Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Proglucagon is a polyprotein precursor containing not only glucagon and glicentin, but glucagon-like peptides-I and -II and an intervening peptide (IP-II). The glucagon gene is expressed in both pancreatic islets and neuroendocrine L-cells of the gastrointestinal tract. We have recently cloned an islet cell line from a rat pancreatic islet cell tumour that simultaneously expresses the glucagon, insulin,
somatostatin
, and
angiotensinogen
genes. We investigated the potential role of "second messenger" pathways in the regulation of glucagon gene expression. Both the tumor promoter agent phorbol myristate acetate (PMA) and a diacylglycerol analog, 1,2-dioctanoylglycerol, induced a 2.7- and 2.5-fold increase in steady-state glucagon mRNA levels at 24 h, respectively. The increase was progressive up to 24 h and was specific for glucagon mRNA; the insulin and
somatostatin
mRNA levels remained unchanged. An inactive phorbol ester, 4 beta-phorbol 12,13,20-triacetate, was without effect. The glucagon mRNA increase induced by PMA was mediated through an increase in glucagon gene transcription reaching maximal stimulation at 30-60 min. Glucagon mRNA half-life was similar in both control and PMA-treated cells, approximating 12 h. The stimulation of glucagon gene transcription was accompanied by a corresponding 3-fold increase in proglucagon biosynthesis. Neither dibutyryl cAMP nor glucocorticoids affected glucagon mRNA levels, while inducing a 5-fold increase in
somatostatin
mRNA levels and 4.8-fold stimulation in
angiotensinogen
mRNA at 24 h, respectively. We conclude that expression of the glucagon gene in this islet cell line is regulated at the level of transcription through a protein kinase C (Ca2+/phospholipid-dependent enzyme)-activated pathway.
...
PMID:Glucagon gene transcription in an islet cell line is regulated via a protein kinase C-activated pathway. 287 43
The developmental origin of the four phenotypically distinct hormone-producing islet cells (insulin, glucagon,
somatostatin
, pancreatic polypeptide) is unclear. To investigate the potential for phenotypic differentiation of islet cells, we prepared several clonal cell lines from a radiation-induced rat islet tumor and analyzed them for insulin, glucagon, and
somatostatin
gene expression by cDNA hybridization, immunocytochemistry, and radioimmunoassay. We found expression of all three genes in the tumor and in the parental cell line and mixed variable phenotypes in the clonal lines derived from the parental line. We also observed the ectopic expression of the
angiotensinogen
gene in the tumor and the cell lines. The relative levels of hormonal gene expression differed among the cell lines but remained fixed during continuous passage. The three islet hormone mRNAs were larger compared to the pancreas owing to longer poly(A) tracts. These observations indicate that neoplastic islet cells retain the potential to differentiate into hormone-specific cellular phenotypes and may mimic developmental pathways of the pancreatic islets.
...
PMID:Multipotential phenotypic expression of genes encoding peptide hormones in rat insulinoma cell lines. 287 52
Renin-like activity (RLA) and angiotensin I-converting enzyme-like activity (ACELA), two key enzymes of the renin-angiotensin cascade (RAS), were sought in the dogfish rectal gland. RLA was 1.1 +/- 0.2 ng Ang I/mg protein/hr after incubation with porcine
angiotensinogen
and 0.8 +/- 0.1 ng Ang I/mg protein/hr after incubation with homologous plasma. ACELA was 7.22 +/- 1.08 and 8.87 +/- 1.9 nmol hippurate generated/min/mg protein respectively, at 0 and 37 degrees. The presence of these enzymes may indicate the presence of an endogenous RAS-like system in the rectal gland. Angiotensin II (Ang II) and atrial natriuretic peptide (ANP) binding sites were demonstrated autoradiographically in the subcapsular region of the gland, suggesting a possible interaction of the two hormones in the blind outer ends of the rectal gland tubules. Immunoreactivities toward Ang II, ANP, bombesin, vasoactive intestinal polypeptide (VIP), glucagon, and
somatostatin
were differentially localized in the rectal gland within three concentric zones with potentially different functional activities. In the capsule, there was a strong positive ir-glucagon reaction and a slightly weaker reaction for ir-
somatostatin
and VIP. In the blind outer ends of the tubules (in the subcapsular zone), strong immunoreactivity was present toward all the tested peptides except glucagon and
somatostatin
. In the inner zone and in the central canal, only a weak immunoreactivity toward Ang II and glucagon was observed.
...
PMID:Renin-like activity, angiotensin I-converting enzyme-like activity, and osmoregulatory peptides in the dogfish rectal gland. 790 83
To identify the nuclear protein(s) that interact with the putative cAMP response element (CRE) of the rat
angiotensinogen
(
ANG
) gene (i.e. nt 806-779 upstream of the transcriptional start site), mouse liver nuclear proteins were prepared for the present studies. The DNase 1 footprinting protection analysis revealed that nt -799/-788 in the 5'-flanking region of the rat
ANG
gene are protected by the mouse liver nuclear protein. Gel mobility-shift assays revealed that the addition of the unlabelled DNA fragment,
ANG
nt -806/-779 competed effectively with the binding of the labelled
ANG
nt -806/-779 to the mouse liver nuclear proteins but the addition of unlabelled mutants of
ANG
nt -806/-779 were only weakly effective in competing with the labelled
ANG
nt -806/-779. The addition of unlabelled CRE of the
somatostatin
(
SOM
) gene and the CRE of the tyrosine aminotransferase (TAT) gene was also ineffective in competing with the labelled
ANG
nt -806/-779. Southwestern blot analysis revealed that the labelled
ANG
nt -806/-779 interacted with two mouse liver nuclear proteins with apparent molecular masses of 52 and 43 kDa, whereas the labelled
SOM
-CRE, TAT-CRE and the CRE of the phosphoenolpyruvate carboxykinase (PEPCK) gene interacted with one molecular species of 43 kDa. The binding of the labelled
ANG
nt -806/-779 to the 52 kDa protein was effectively competed for by the addition of unlabelled
ANG
nt -806/-779 but not by unlabelled
SOM
-CRE, TAT-CRE and PEPCK-CRE. Finally, Western blot analysis revealed that polyclonal antibodies against the CRE-binding protein (CREB) interacted with the mouse liver nuclear 43 kDa protein but not with the 52 kDa protein. These studies demonstrate that the CRE of the rat
ANG
gene (
ANG
nt -806/-779) interacts with the 43 kDa CREB and a novel 52 kDa protein from mouse liver. The novel 52 kDa protein is immunologically distinct from the 43 kDa CREB. These studies suggest that the 52 kDa protein might have a role in the expression of the hepatic
ANG
gene.
...
PMID:Identification of a novel mouse hepatic 52 kDa protein that interacts with the cAMP response element of the rat angiotensinogen gene. 944 91
To investigate the molecular mechanism(s) of action of catecholamines on the expression of the
angiotensinogen
(
ANG
) gene in kidney proximal tubular cells, we used opossum kidney (OK) cells with a fusion gene containing the 5'-flanking regulatory sequence of the rat
ANG
gene fused with a human growth hormone (hGH) gene as a reporter, pOGH (rANG N-1498/+18), permanently integrated into their genomes. The level of expression of the
ANG
-GH fusion gene was quantified by the amount of immunoreactive-hGH (IR-hGH) secreted into the medium. The addition of norepinephrine (NE), isoproterenol (a beta1/beta2-adrenergic receptor (AR) agonist) and iodoclonidine (an alpha2-AR agonist) stimulated the expression of the
ANG
-GH fusion gene in a dose-dependent manner, whereas the addition of epinephrine and phenylephrine (alpha1-AR agonist) had no effect. The stimulatory effect of NE was blocked by the presence of propranolol (beta-AR blocker), atenolol (beta1-AR blocker), yohimbine (alpha2-AR blocker), Rp-cAMP (an inhibitor of cAMP-dependent protein kinase AI & AII) and staurosporine (an inhibitor of protein kinase C), but was not blocked by ICI 118, 551 (beta2-AR blocker) and prazosin (alpha1-AR blocker). The addition of a combination of isoproterenol and iodoclonidine or a combination of 8-Bromo-cAMP (8-Br-cAMP) and phorbol 12-myristate (PMA) synergistically stimulated the expression of the
ANG
-GH fusion gene as compared to the addition of isoproterenol, iodoclonidine, 8-Br-cAMP or PMA alone. Furthermore, the addition of NE, 8-Br-cAMP or PMA stimulated the expression of pOGH (rANG N-806/-779/-53/+18), a fusion gene containing the putative cAMP responsive element (CRE,
ANG
N-806/-779) upstream of the
ANG
promoter (
ANG
N-53/+18) in OK cells, but had no effect on the expression of fusion genes containing the mutant of the CRE. Gel mobility shift assays revealed that the
ANG
-CRE binds with the DNA-binding domain (bZIP254-327) of the cAMP-responsive binding protein (CREB). The binding of the labeled
ANG
-CRE to CREB (bZIP254-327) was displaced by unlabeled
ANG
-CRE and the CRE of the
somatostatin
gene but not by the mutants of the
ANG
-CRE. Finally, NE stimulated the phosphorylation of CREB in OK cells. These studies demonstrate that the molecular mechanism(s) of NE action on the expression of the
ANG
gene in OK cells may be mediated via both the PKA and PKC signalling pathways and via the phosphorylation of CREB. The phosphorylated CREB then interacts with the CRE in the 5'-flanking region of the
ANG
gene and subsequently stimulates the gene expression.
...
PMID:Catecholamines and angiotensinogen gene expression in kidney proximal tubular cells. 1110 38
Elevated plasma
angiotensinogen
(
AGT
) levels have been demonstrated in insulin-resistant states such as obesity and type 2 diabetes mellitus (DM2), conditions that are directly correlated to hypertension. We examined whether hyperinsulinemia or hyperglycemia may modulate fat and liver
AGT
gene expression and whether obesity and insulin resistance are associated with abnormal
AGT
regulation. In addition, because the hexosamine biosynthetic pathway is considered to function as a biochemical sensor of intracellular nutrient availability, we hypothesized that activation of this pathway would acutely mediate in vivo the induction of
AGT
gene expression in fat and liver. We studied chronically catheterized lean (approximately 300 g) and obese (approximately 450 g) Sprague-Dawley rats in four clamp studies (n = 3/group), creating physiological hyperinsulinemia (approximately 60 microU/ml, by an insulin clamp), hyperglycemia (approximately 18 mM, by a pancreatic clamp using
somatostatin
to prevent endogenous insulin secretion), or euglycemia with glucosamine infusion (GlcN; 30 micromol. kg(-1). min(-1)) and equivalent saline infusions (as a control). Although insulin infusion suppressed
AGT
gene expression in fat and liver of lean rats, the obese rats demonstrated resistance to this effect of insulin. In contrast, hyperglycemia at basal insulin levels activated
AGT
gene expression in fat and liver by approximately threefold in both lean and obese rats (P < 0.001). Finally, GlcN infusion simulated the effects of hyperglycemia on fat and liver
AGT
gene expression (2-fold increase, P < 0.001). Our results support the hypothesis that physiological nutrient "pulses" may acutely induce
AGT
gene expression in both adipose tissue and liver through the activation of the hexosamine biosynthetic pathway. Resistance to the suppressive effect of insulin on
AGT
expression in obese rats may potentiate the effect of nutrients on
AGT
gene expression. We propose that increased
AGT
gene expression and possibly its production may provide another link between obesity/insulin resistance and hypertension.
...
PMID:Hyperglycemia modulates angiotensinogen gene expression. 1150 94